He Jing-Yu, Zhou Xue-Qin, Wang Wen-Tao
Department of Liver Surgery,West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Hepatobiliary and Pancreatic Surgery, the Third Hospital of Mianyang and Sichuan Mental Health Center, Mianyang 621000, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Sep;53(5):744-751. doi: 10.12182/20220960505.
To examine the relationship between miRNA-3679 and hepatocellular carcinoma (HCC) cell lines, and to verify the downstream target genes of miRNA-3679.
PCR was used to determine the expression of miRNA-3679 in liver cancer cell lines, and databases, including ENCORI, miRDB and TargetScan, were used to predict the downstream target genes of miRNA-3679. qPCR of the normal control group (or NC group), miR-3679 inhibitor group and transfection negative control group (or inhibitor NC group) was done to determine the transfection efficiency of the target gene, thereby identifying zinc-binding alcohol dehydrogenase domain containing 2 () as the target gene. Western blot was used to determine the ZADH2 protein expression after miRNA-3679 inhibitor transfection. 5-Ethynyl-2'-deoxyuridine (EdU) staining was done to determine the effect of transfection of miRNA-3679 inhibitor and simultaneous transfection of miRNA-3679 and ZADH2 inhibitors on cell proliferation. Clone formation assay was done to determine the ability of cell clone formation. Flow cytometry was done to examine cell apoptosis.
The expression level of miRNA-3679 in HCC cell lines was higher than that in normal human liver cell lines (<0.05). Through screening conducted with the databases, six genes, including 1, 31, 463, 23, 5, and 2, were found to be down-regulated in HCC. qPCR showed that 2 expression increased significantly after transfection with miRNA-3679 inhibitor (<0.01) and luciferase activity increased after transfection with miR-3679 inhibitor (<0.01). Western blot results showed that ZADH2 protein expression of the miR-3679 inhibitor group was higher than that of the NC group (<0.01). EdU analysis showed that the number of positive cells in the miRNA-3679 inhibitor group was lower than that in the NC group and the Inhibitor NC group (<0.05). The clone count of the miR-3679 inhibitor+si-2 group was significantly higher than that of the miR-3679 inhibitor group (<0.01). Flow cytometry showed that the number of apoptotic cells of the miR-3679 inhibitor+si-2 group was significantly lower than that of the miR-3679 inhibitor group (<0.01).
miRNA-3679 is significantly highly expressed in HCC cells and miRNA-3679 can directly interact with 2 gene and affect its expression. Moreover, miRNA-3679 promotes the proliferation of HCC cells and inhibits their apoptosis by suppressing ZADH2.
研究miRNA - 3679与肝癌(HCC)细胞系之间的关系,并验证miRNA - 3679的下游靶基因。
采用PCR检测miRNA - 3679在肝癌细胞系中的表达,并利用包括ENCORI、miRDB和TargetScan在内的数据库预测miRNA - 3679的下游靶基因。对正常对照组(或NC组)、miR - 3679抑制剂组和转染阴性对照组(或抑制剂NC组)进行qPCR,以确定靶基因的转染效率,从而鉴定含锌结合醇脱氢酶结构域2(ZADH2)为靶基因。采用蛋白质免疫印迹法检测miRNA - 3679抑制剂转染后ZADH2蛋白的表达。进行5 - 乙炔基 - 2'-脱氧尿苷(EdU)染色,以确定miRNA - 3679抑制剂转染以及miRNA - 3679与ZADH2抑制剂同时转染对细胞增殖的影响。进行克隆形成实验以确定细胞克隆形成能力。采用流式细胞术检测细胞凋亡情况。
HCC细胞系中miRNA - 3679的表达水平高于正常人肝细胞系(P<0.05)。通过数据库筛选,发现包括ZADH2在内的6个基因在HCC中表达下调。qPCR结果显示,转染miRNA - 3679抑制剂后ZADH2表达显著增加(P<0.01),转染miR - 3679抑制剂后荧光素酶活性增加(P<0.01)。蛋白质免疫印迹结果显示,miR - 3679抑制剂组的ZADH2蛋白表达高于NC组(P<0.01)。EdU分析显示,miRNA - 3679抑制剂组的阳性细胞数低于NC组和抑制剂NC组(P<0.05)。miR - 3679抑制剂 + si - ZADH2组的克隆数显著高于miR - 3679抑制剂组(P<0.01)。流式细胞术显示,miR - 3679抑制剂 + si - ZADH2组的凋亡细胞数显著低于miR - 3679抑制剂组(P<0.01)。
miRNA - 3679在HCC细胞中显著高表达,且miRNA - 3679可直接与ZADH2基因相互作用并影响其表达。此外,miRNA - 3679通过抑制ZADH2促进HCC细胞增殖并抑制其凋亡。